Pathogenesis and pharmacological treatment of bone pain in skeletal metastases

C. Ripamonti, F. Fulfaro

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Sixty-five percent of patients with advanced cancer present bone metastases and most of them present a rather slow clinical course characterized by pain, mobility deficiences and skeletal complications such as fractures and spinal cord compression. Metastatic involvement of the bone is one of the most frequent causes of pain in cancer patients and represents one of the first signs of widespread neoplastic disease. The pain may originate directly from the bone, from nerve root compression or from muscle spasms in the area of the lesions. The mechanisms of metastatic bone pain is mainly somatic (nociceptive) even though, in some cases, neuropathic and visceral stimulations may overlap. The conventional symptomatic treatment of metastatic bone pain requires the use of multidisciplinary therapies such as radiotherapy in association with systemic treatment (hormonotherapy, chemotherapy, radioisotopes) with the support of analgesic therapy. Recently, studies have indicated the use of bisphosphonates in the treatment of pain and in the prevention of skeletal complications in patients with metastatic bone disease. In some patients pharmacological treatment, radiotherapy, radioisotopes administered alone or in association are not able to manage pain adequately. The role of neuroinvasive techniques in treating metastatic bone pain is debated. The clinical conditions of the patient, his life expectancy and quality of life must guide the physician in the choice of the best possible therapy.

Original languageEnglish
Pages (from-to)65-77
Number of pages13
JournalQuarterly Journal of Nuclear Medicine
Volume45
Issue number1
Publication statusPublished - 2001

Fingerprint

Pharmacology
Neoplasm Metastasis
Bone and Bones
Pain
Radioisotopes
Therapeutics
Radiotherapy
Quality of Life
Bone Neoplasms
Spinal Cord Compression
Radiculopathy
Bone Diseases
Diphosphonates
Spasm
Life Expectancy
Analgesics
Physicians
Drug Therapy

Keywords

  • Bone neoplasms, drug therapy
  • Bone neoplasms, radiotherapy
  • Bone neoplasms, secondary
  • Pain, therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Pathogenesis and pharmacological treatment of bone pain in skeletal metastases. / Ripamonti, C.; Fulfaro, F.

In: Quarterly Journal of Nuclear Medicine, Vol. 45, No. 1, 2001, p. 65-77.

Research output: Contribution to journalArticle

@article{ee219a7173274845a46c9081dd98a543,
title = "Pathogenesis and pharmacological treatment of bone pain in skeletal metastases",
abstract = "Sixty-five percent of patients with advanced cancer present bone metastases and most of them present a rather slow clinical course characterized by pain, mobility deficiences and skeletal complications such as fractures and spinal cord compression. Metastatic involvement of the bone is one of the most frequent causes of pain in cancer patients and represents one of the first signs of widespread neoplastic disease. The pain may originate directly from the bone, from nerve root compression or from muscle spasms in the area of the lesions. The mechanisms of metastatic bone pain is mainly somatic (nociceptive) even though, in some cases, neuropathic and visceral stimulations may overlap. The conventional symptomatic treatment of metastatic bone pain requires the use of multidisciplinary therapies such as radiotherapy in association with systemic treatment (hormonotherapy, chemotherapy, radioisotopes) with the support of analgesic therapy. Recently, studies have indicated the use of bisphosphonates in the treatment of pain and in the prevention of skeletal complications in patients with metastatic bone disease. In some patients pharmacological treatment, radiotherapy, radioisotopes administered alone or in association are not able to manage pain adequately. The role of neuroinvasive techniques in treating metastatic bone pain is debated. The clinical conditions of the patient, his life expectancy and quality of life must guide the physician in the choice of the best possible therapy.",
keywords = "Bone neoplasms, drug therapy, Bone neoplasms, radiotherapy, Bone neoplasms, secondary, Pain, therapy",
author = "C. Ripamonti and F. Fulfaro",
year = "2001",
language = "English",
volume = "45",
pages = "65--77",
journal = "Journal of Nuclear Medicine and Allied Sciences",
issn = "1124-3937",
publisher = "Minerva Medica",
number = "1",

}

TY - JOUR

T1 - Pathogenesis and pharmacological treatment of bone pain in skeletal metastases

AU - Ripamonti, C.

AU - Fulfaro, F.

PY - 2001

Y1 - 2001

N2 - Sixty-five percent of patients with advanced cancer present bone metastases and most of them present a rather slow clinical course characterized by pain, mobility deficiences and skeletal complications such as fractures and spinal cord compression. Metastatic involvement of the bone is one of the most frequent causes of pain in cancer patients and represents one of the first signs of widespread neoplastic disease. The pain may originate directly from the bone, from nerve root compression or from muscle spasms in the area of the lesions. The mechanisms of metastatic bone pain is mainly somatic (nociceptive) even though, in some cases, neuropathic and visceral stimulations may overlap. The conventional symptomatic treatment of metastatic bone pain requires the use of multidisciplinary therapies such as radiotherapy in association with systemic treatment (hormonotherapy, chemotherapy, radioisotopes) with the support of analgesic therapy. Recently, studies have indicated the use of bisphosphonates in the treatment of pain and in the prevention of skeletal complications in patients with metastatic bone disease. In some patients pharmacological treatment, radiotherapy, radioisotopes administered alone or in association are not able to manage pain adequately. The role of neuroinvasive techniques in treating metastatic bone pain is debated. The clinical conditions of the patient, his life expectancy and quality of life must guide the physician in the choice of the best possible therapy.

AB - Sixty-five percent of patients with advanced cancer present bone metastases and most of them present a rather slow clinical course characterized by pain, mobility deficiences and skeletal complications such as fractures and spinal cord compression. Metastatic involvement of the bone is one of the most frequent causes of pain in cancer patients and represents one of the first signs of widespread neoplastic disease. The pain may originate directly from the bone, from nerve root compression or from muscle spasms in the area of the lesions. The mechanisms of metastatic bone pain is mainly somatic (nociceptive) even though, in some cases, neuropathic and visceral stimulations may overlap. The conventional symptomatic treatment of metastatic bone pain requires the use of multidisciplinary therapies such as radiotherapy in association with systemic treatment (hormonotherapy, chemotherapy, radioisotopes) with the support of analgesic therapy. Recently, studies have indicated the use of bisphosphonates in the treatment of pain and in the prevention of skeletal complications in patients with metastatic bone disease. In some patients pharmacological treatment, radiotherapy, radioisotopes administered alone or in association are not able to manage pain adequately. The role of neuroinvasive techniques in treating metastatic bone pain is debated. The clinical conditions of the patient, his life expectancy and quality of life must guide the physician in the choice of the best possible therapy.

KW - Bone neoplasms, drug therapy

KW - Bone neoplasms, radiotherapy

KW - Bone neoplasms, secondary

KW - Pain, therapy

UR - http://www.scopus.com/inward/record.url?scp=0034955238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034955238&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 65

EP - 77

JO - Journal of Nuclear Medicine and Allied Sciences

JF - Journal of Nuclear Medicine and Allied Sciences

SN - 1124-3937

IS - 1

ER -